The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 23 of the 62 sources its claims cite were checked for support.
Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation
Open accessAbstract
Preclinical studies demonstrate that rapid acting antidepressants, including ketamine require stimulation of mTORC1 signaling. This pathway is regulated by neuronal activity, endocrine and metabolic signals, notably the amino acid leucine, which activates mTORC1 signaling via binding to the upstream regulator sestrin. Here, we examined the antidepressant actions of NV-5138, a novel highly selective small molecule modulator of sestrin that penetrates the blood brain barrier. The results demonstrate that a single dose of NV-5138 produced rapid and long-lasting antidepressant effects, and rapidly reversed anhedonia caused by chronic stress exposure. The antidepressant actions of NV-5138 required BDNF release as the behavioral responses are blocked by infusion of a BDNF neutralizing antibody into the medial prefrontal cortex (mPFC) or in mice with a knock-in of a BDNF polymorphism that blocks activity dependent BDNF release. NV-5138 administration also rapidly increased synapse number and function in the mPFC, and reversed the synaptic deficits caused by chronic stress. Together, the results demonstrate that NV-5138 produced rapid synaptic and antidepressant behavioral responses via activation of the mTORC1 pathway and BDNF signaling, indicating that pharmacological modulation of sestrin is a novel approach for development of rapid acting antidepressants.
Overview
CoChat Summary
TL;DR
NV-5138, a brain-penetrant sestrin modulator, produced rapid and long-lasting antidepressant-like behavioral effects and reversed chronic stress–induced synaptic deficits in rodents. These effects required mTORC1 signaling and BDNF and were accompanied by increased synapse number and function in the medial prefrontal cortex.
Key findings
- A single oral dose of NV-5138 at 160 mg/kg, but not 40 or 80 mg/kg, significantly reduced immobility in the FST and latency to feed in the NSFT; leucine (160 mg/kg) had no effect.
- Single-dose NV-5138 and ketamine (10 mg/kg) produced antidepressant-like effects lasting up to 7 days in the FST, while repeated low-dose NV-5138 (80 mg/kg daily for 7 days) also significantly reduced immobility and latency to feed.
- NV-5138 rapidly reversed chronic unpredictable stress–induced decreases in sucrose preference and increased NSFT latency, and reversed CUS-induced reductions in mPFC GluR1 and PSD95.
- The behavioral actions of NV-5138 were blocked by intra-mPFC rapamycin or BDNF-neutralizing antibody and were absent in BDNF Val/Met and Met/Met knockin mice; NV-5138 also increased hypocretin-induced EPSC frequency, spine density, and synaptic proteins in mPFC.
Methods
- Male Sprague-Dawley rats (250–260 g; 120–140 g for CUS) and BDNF Val66Met knockin mice (8–12 weeks) were used; NV-5138 was given orally, ketamine intraperitoneally, and rapamycin, BDNF nAb, or IgG were infused into the mPFC.
- Behavioral assays included FST, NSFT, FUST, locomotor activity, home-cage feeding, and sucrose preference; CUS consisted of 21 days of variable stressors (13 stressors, 2 per day).
- Mechanistic measures included Western blots of synaptosomal PFC proteins, whole-cell patch recordings of layer V pyramidal neurons, and confocal spine analysis; data were analyzed with ANOVA/Tukey tests or Student’s t tests, with significance at P ≤ 0.05.
Limitations
- The authors state that the CUS conclusion is tempered because they did not test the influence of NV-5138 on mTORC1 signaling in CUS-exposed rats.
- The authors note that NBQX pretreatment did not block the FST effect and only partially, nonsignificantly blocked the NSFT effect, but state that higher or additional NBQX doses could reveal an AMPA receptor requirement.
- The authors state that further studies are needed to assess side effects in rodents and primates, including whether mTORC1 activation could influence tumor growth; the text also makes evident that the findings are preclinical and most behavioral studies used male rats.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
11 Valid · 0 Not valid · 21 Not checked · 75 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Preclinical studies demonstrate that rapid-acting antidepressants, including ketamine, require stimulation of mTORC1 signaling.”
What the sources say
- Supportedcites [7] source
The passages on ketamine’s behavioral effects and Ro 25-6981 (passages 4 and 5, labeled Abstract in our copy) report rapid antidepressant-like effects in preclinical tests that were blocked by rapamycin. The paper also reports activation of mTOR signaling by both drugs, supporting the attributed requirement for this pathway in the agents studied. (LLM, conf=0.90)
- Partly supportedcites [8] sourceExperimental — accuracy not yet measured
The Results report that rapamycin blocked ketamine’s reversal of behavioral deficits in chronically stressed rats, supporting a requirement for mTOR signaling in that preclinical model. The paper describes a rapamycin-sensitive mTOR pathway but does not identify it specifically as mTORC1 or establish this requirement for rapid-acting antidepressants generally. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“recent studies demonstrate that a single, subanesthetic dose of ketamine produces rapid (within hours) and long-lasting (7 to 10 days) antidepressant effects even in patients who have failed to respond to traditional antidepressants and are considered treatment resistant (5, 6).”
What the sources say
- Partly supportedcites [5] sourceExperimental — accuracy not yet measured
The INTRODUCTION and the section 'THE RAPID ANTIDEPRESSANT EFFECTS OF KETAMINE' support most of the claim: a single low (subanesthetic) IV dose produced effects within 4 h in severely treatment-resistant/refractory depressed patients, replicated across five placebo-controlled studies, with effects persisting for two weeks or longer in some patients. However, the specific duration the citing sentence attributes — 'long-lasting (7 to 10 days)' — is not what our copy states: the controlled-study figure given is 'sustained for 3–7 days' with a 40–60% response rate at 24 h, and the longer durations are described only as occurring 'in some patients'. The 7–10 day magnitude is therefore an extrapolation beyond the source's stated figures. (LLM, conf=0.70)
- Not checked yetcites [6] source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As expected, a single dose of NV-5138 (160 mg/kg) rapidly increased levels of phospho-mTOR as well as the downstream targets, phospho-p70S6K1, and phospho-4EB-P1, in synaptosomal preparations of PFC (Figure 4, C-E), confirming recent studies (22).”
What the sources say
- Partly supportedcites [22] sourceExperimental — accuracy not yet measured
The Results section (Pharmacokinetics and Pharmacodynamics; page not available) reports increased phosphorylated S6 in PFC synaptoneurosomes one hour after a 160 mg/kg dose, supporting rapid mTORC1 activation. It does not report increased phospho-mTOR, phospho-p70S6K1, or phospho-4EB-P1 in those preparations; those specific measurements are not supported by our copy. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The BDNF Met polymorphism blocks the processing and activity-dependent release of mature BDNF (33).”
What the sources say
- Partly supportedcites [33] sourceExperimental — accuracy not yet measured
The passage labeled Abstract reports an approximately 30% reduction in activity-dependent BDNF release, not a block. It also says neuronal studies suggest no defect in BDNFMet processing, although additional processing defects remain possible. The claim therefore overstates the release finding and is not supported on processing. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies demonstrate that infusion of rapamycin alone into the mPFC has no effect on these behaviors (7, 8, 10, 12).”
What the sources say
- Could not verifycites [7] sourceExperimental — accuracy not yet measured
The passage labeled Abstract describing Fig. 3D–E says that rapamycin infused into the medial PFC blocked ketamine’s behavioral effects in the forced swim and novelty-suppressed feeding tests. It does not report the behavioral effects of rapamycin infused alone; searches for that comparison found no passage addressing it. (LLM, conf=0.72)
- Partly supportedcites [8] sourceExperimental — accuracy not yet measured
The Results report that rapamycin alone had no effect in the sucrose preference or novelty-suppressed feeding tests in stressed rats. However, the Results and Materials and Methods specify infusion into the lateral ventricles (ICV), not into the mPFC; that location is unsupported by this paper. (LLM, conf=0.90)
- Supportedcites [10] source
The Fig. 4 caption (Materials and Methods; page not specified) reports that rapamycin infused into the mPFC alone had no effect on immobility time or latency to feed, the behaviors tested in the FST and NSFT. (LLM, conf=0.94)
- Partly supportedcites [12] sourceExperimental — accuracy not yet measured
The Results section reports that a previous study found no effect of rapamycin alone on immobility in the forced swim test. But it specifies an intracerebroventricular (i.c.v.) injection, not an infusion into the mPFC, and does not establish no effect on other behaviors. (LLM, conf=0.87)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
59 more claims · 2 with their cited sources checked
Create a free account to see all 107 claims and to verify the 39 references still open.
- It may state two separate claims as one. 29
- The quote only partly states this claim. 1
- Probably not a substantial claim. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“work from our group and others has shown that quantification of SV2A is similar to that of other markers of synaptic density in clinical samples and after drug challenge”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [71]
Experimental — accuracy not yet measuredIn the citing paper
“Work by Ron Duman, in collaboration with our group, demonstrated elevated synaptic protein expression, including SV2A, in the prefrontal cortex of rats 24-hours (time comparable to human peak antidepressant effects) after a single subanesthetic dose of ketamine (10 mg/kg)”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 5
“2-way ANOVA and Tukey's multiple comparison test.”
§ Results · p. 5
“1-way ANOVA ( B -D , F , G ) and Student's t test ( E ).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 4
“Figure 2. Single-dose NV-5183 produces long-lasting antidepressant effects, and repeated low-dose NV-5138 also produces antidepressant effects.”
§ Results · p. 4
“Three or seven days after NV-5138 (160 mg/kg) or ketamine (10 mg/kg) administration, the FST was conducted.”
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Willner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
Zoncu, R., Bar-Peled, L., Efeyan, A., Wang, S., Sancak, Y., & Sabatini, D. M. (2011) · Science · doi:10.1126/science.1207056 · Cited by 1,673
Willner, P. (2005) · Neuropsychobiology · doi:10.1159/000087097 · Cited by 1,605
Research works printed but not linked: 2
- 10.1002/(sici)1097-4644(20000501)77:2 · doi:10.1002/(sici)1097-4644(20000501)77:2
- 10.1146/annurev-med-053013-062946 · DOI · Paper page
Cited by
mTOR at the nexus of nutrition, growth, ageing and disease
Liu, G. Y., & Sabatini, D. M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0199-y · Cited by 2,737
Goul, C., Peruzzo, R., & Zoncu, R. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00641-8 · Cited by 269
Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
“The role of mTOR in antidepressant action is also supported by evidence of antidepressant activity of a direct mTOR activator [126, 127].”
BackgroundThe stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders
Sanacora, G., Yan, Z., & Popoli, M. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00540-x · Cited by 197
Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine
Deyama, S., & Duman, R. S. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172837 · Cited by 186
“, 2019) and NV-5138 (an mTORC1 activator; see above) (Kato et al., 2019).”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Kato, T., Pothula, S., Liu, R.-J., Duman, C. H., Terwilliger, R., Vlasuk, G. P., Saiah, E., Hahm, S., & Duman, R. S.
- Affiliations
- Sumitomo Dainippon Pharma (Japan) (JP)
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- Venue
- Journal of Clinical Investigation
- Published
- 2019-05-20
- Volume
- 129
- Issue
- 6
- Pages
- 2542-2554
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6546461
- OpenAlex
- W2936807256
- Semantic Scholar
- 12f7e7e41f49a3362421ed722b77861aaed57af9
- Cited by
- 88
- References
- 50
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 7 · 2023: 8 · 2022: 18 · 2021: 16 · 2020: 14 · 2019: 4
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIMH, Navitor Pharmaceuticals Inc. (MH093897,MH105910)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- sestrins, mTORC1 signaling, rapid-acting antidepressants, antidepressant effects, brain-derived neurotrophic factor, chronic stress, anhedonia, medial prefrontal cortex, synapse number, synaptic deficits, leucine, blood-brain barrier, ketamine
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Animals, Antidepressive Agents, Behavior, Animal, Heat-Shock Proteins, Male, Synaptic Transmission, Rats, Sprague-Dawley, Mice, Knockout, Brain-Derived Neurotrophic Factor, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation. https://app.cochat.ai/papers/10.1172/jci126859
- The paper
- Kato, T., Pothula, S., Liu, R.-J., Duman, C. H., Terwilliger, R., Vlasuk, G. P., Saiah, E., Hahm, S., & Duman, R. S. (2019). Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation. Journal of Clinical Investigation. https://doi.org/10.1172/jci126859
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.